Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740779 · ClinicalTrials.gov registry record · Phase 2
Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
A Phase 2 study of Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT00740779: Completed Phase 2 study of Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome, sponsored by Watson Pharmaceuticals.
NCT00740779 is a Phase 2 study of Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 153 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00740779, a Phase 2 study of Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.
Primary Outcome
Change from baseline In NIH-CPSI at Week 12. Three separate domain scores are calculated as pain, urinary symptoms, and quality of life impact. NIH-CPSI total score uses a 0 to 43 scale; 0 best, 43 worse symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Silodosin 8 mg
- DRUG Silodosin 4 mg
Study Locations (20)
New York
- Watson Investigational Site - Garden City
- Watson Investigational Site - Kingston
- Watson Investigational Site - New York
- Watson Investigational Site - Poughkeepsie
Georgia
- Watson Investigational Site - Columbus
- Watson Investigational Site - Roswell
Massachusetts
- Watson Investigational Site - Boston
- Watson Investigational Site - Watertown
Oklahoma
- Watson Investigational Site - Bethany
- Watson Investigational Site - Edmond
California
- Watson Investigational Site - San Diego
Colorado
- Watson Investigational Site - Denver
Indiana
- Watson Investigational Site - Jeffersonville
Iowa
- Watson Investigational Site - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT00740779 record still lists
NCT00740779 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher).
The record links to 1 condition, with Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00740779 names 20 study sites across 14 states, led by New York, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00740779 about?
NCT00740779 is a clinical study titled "Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.". The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of sil...
What is the current status of trial NCT00740779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2008-09. Estimated completion is 2009-10.
What conditions does trial NCT00740779 study?
This clinical trial studies the following conditions: Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
What interventions are being tested in trial NCT00740779?
The interventions under investigation include: Placebo (DRUG), Silodosin 8 mg (DRUG), Silodosin 4 mg (DRUG).
Who is sponsoring clinical trial NCT00740779?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00740779 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00740779's enrollment target sits among peer trials
153 449th of 2000 higher than 1,549 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia